US Patent Issued to GlaxoSmithKline Intellectual Property Development on Feb. 18 for "Anti-BCMA antibody drug conjugate combination treatment for cancer" (Pennsylvania Inventors)

ALEXANDRIA, Va., Feb. 19 -- United States Patent no. 12,227,585, issued on Feb. 18, was assigned to GlaxoSmithKline Intellectual Property Development Ltd. (Stevenage, Great Britain).

"Anti-BCMA antibody drug conjugate combination treatment for cancer" was invented by Sanjay Khandekar (Collegeville, Pa.), Patrick Mayes (Devon, Pa.) and Joanna Opalinska (Collegeville, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compo...